Study of the effect of medicinal product "STRESSEN" on blood levels of homocysteine in patients with current cardiovascular disease
OBJECTIVE: The relationship between cardiovascular disease and high plasma levels of homocysteine is known; it is therefore necessary to keep the concentrations of this amino acid, considered an independent risk factor for these pathologies, within the physiological range. The objective of this study is to evaluate the efficacy of the medicinal product STRESSEN on homocysteinemia in patients with current cardiovascular disease.
PATIENTS AND METHODS: The study was carried out on 40 patients with homocysteinemia higher than 14 micromol/l. Patients were divided into 2 groups of 20: one was treated with STRESSEN for 30 days and the other did not receive any specific therapy. Homocysteinemia was evaluated at t = 0 and t = 30 days in both groups.
RESULTS: STRESSEN determined a significative mean reduction of 39.2% (P < 0.0001) of plasma levels of the considered amino acid, which on the contrary did not change in non treated patients.
CONCLUSIONS: The results of this study show the efficacy of STRESSEN in reducing homocysteinemia and, consequently, the risk of coronary disease.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2004 |
|---|---|
| Erschienen: |
2004 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:155 |
|---|---|
| Enthalten in: |
La Clinica terapeutica - 155(2004), 1 vom: 21. Jan., Seite 13-5 |
| Sprache: |
Italienisch |
|---|
| Weiterer Titel: |
Studio dell'effetto della specialità medicinale "STRESSEN" sui livelli ematici di omocisteina in pazienti con patologia cardiovascolare in atto |
|---|
| Beteiligte Personen: |
Bovenzi, F [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 24.08.2004 Date Revised 21.11.2013 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM148370470 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM148370470 | ||
| 003 | DE-627 | ||
| 005 | 20231223045438.0 | ||
| 007 | tu | ||
| 008 | 231223s2004 xx ||||| 00| ||ita c | ||
| 028 | 5 | 2 | |a pubmed24n0495.xml |
| 035 | |a (DE-627)NLM148370470 | ||
| 035 | |a (NLM)15147075 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ita | ||
| 100 | 1 | |a Bovenzi, F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Study of the effect of medicinal product "STRESSEN" on blood levels of homocysteine in patients with current cardiovascular disease |
| 246 | 3 | 3 | |a Studio dell'effetto della specialità medicinale "STRESSEN" sui livelli ematici di omocisteina in pazienti con patologia cardiovascolare in atto |
| 264 | 1 | |c 2004 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 24.08.2004 | ||
| 500 | |a Date Revised 21.11.2013 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: The relationship between cardiovascular disease and high plasma levels of homocysteine is known; it is therefore necessary to keep the concentrations of this amino acid, considered an independent risk factor for these pathologies, within the physiological range. The objective of this study is to evaluate the efficacy of the medicinal product STRESSEN on homocysteinemia in patients with current cardiovascular disease | ||
| 520 | |a PATIENTS AND METHODS: The study was carried out on 40 patients with homocysteinemia higher than 14 micromol/l. Patients were divided into 2 groups of 20: one was treated with STRESSEN for 30 days and the other did not receive any specific therapy. Homocysteinemia was evaluated at t = 0 and t = 30 days in both groups | ||
| 520 | |a RESULTS: STRESSEN determined a significative mean reduction of 39.2% (P < 0.0001) of plasma levels of the considered amino acid, which on the contrary did not change in non treated patients | ||
| 520 | |a CONCLUSIONS: The results of this study show the efficacy of STRESSEN in reducing homocysteinemia and, consequently, the risk of coronary disease | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Controlled Clinical Trial | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Homocysteine |2 NLM | |
| 650 | 7 | |a 0LVT1QZ0BA |2 NLM | |
| 650 | 7 | |a Folic Acid |2 NLM | |
| 650 | 7 | |a 935E97BOY8 |2 NLM | |
| 650 | 7 | |a Vitamin B 12 |2 NLM | |
| 650 | 7 | |a P6YC3EG204 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t La Clinica terapeutica |d 1958 |g 155(2004), 1 vom: 21. Jan., Seite 13-5 |w (DE-627)NLM000039187 |x 1972-6007 |7 nnns |
| 773 | 1 | 8 | |g volume:155 |g year:2004 |g number:1 |g day:21 |g month:01 |g pages:13-5 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 155 |j 2004 |e 1 |b 21 |c 01 |h 13-5 | ||